# 1AC—COVID

### 1AC – Contention 1: Disease War

#### Developing countries need assistance – the US is key

Stone 21 – Judy Stone is an Infectious Disease specialist; “Covid Vaccine Equity - Developing Countries Need Our Help”; Forbes, May 11, 2021; <https://www.forbes.com/sites/judystone/2021/05/11/vaccine-equitydeveloping-countries-need-our-help/?sh=10939a363ec8> //advay

A few months ago India was doing relatively well and the U.S. was getting crushed by a devastating second Covid-19 wave. Now it’s the reverse. Public health measures were implemented too sporadically (U.S.) and reversed too quickly (both), with predictable results. While the U.S. is beginning to focus attention on the growing catastrophe in India, not enough attention is being given to other areas in the region. Countries like Bangladesh, Nepal, Pakistan, Laos and others in the region may soon be matching the explosive growth of Covid in India. Nepal is one of the poorest countries. Although it has a population of 30 million people, there are only 1595 ICU beds and 480 ventilators throughout the entire country. (This is not much less than in India, at ~1 ICU bed/19,000, but the US has ~1/3800). There are only 80 physicians per 100,000 people, compared to 93 per 100,000 in India or 259 per 100,000 in the US. With a 50% positivity rate for Covid testing, how long do you think those few beds and limited healthcare will last before being completely overwhelmed. Cases in Nepal have increased by 1,645% in the past month. Thailand had a similar rate of increase, with most of their cases being the U.K. variant B.1.1.7, which is known to be more transmissible. Part of the problem in Nepal is that its Prime Minister, Oli, like India’s PM Modi, and Donald Trump had allowed religious festivals and large political gatherings to continue as politically expedient, at the expense of public health and safety. Heavily reliant on tourism to support its economy, Mount Everest has been opened to climbers; there have been outbreaks reported from the base camp although the government has denied this. And much as our former president recommended injecting bleach, PM Oli has reportedly suggested gargling with guava leaves, which is at least less immediately hazardous, although still as useless as treatment. This uncontrolled pandemic will endanger us all by increasing the likelihood of further mutations emerging and spreading globally. India has a new “variant of interest,” called B.1.617⁠, which is also spread more rapidly. The South African variant, B.1.351, is also circulating in India, along with the UK’s B.1.1.7⁠. This—and the huge number of cases—are what prompted the US to ban travel from India. One of the problems in the region is that India’s Serum Institute was to supply much of the area with vaccines. Instead, India is desperate, unable to meet its own country’s needs, and has banned the export of vaccines. Nepal has instead turned to China and Russia, who are engaging in vaccine diplomacy who are donating supplies while the US has been sitting on the sidelines.

#### It’s not too late---COVID will continue across the developing worlds for years to come. Plus, the plan helps for black swan future pandemics.

Brink **Lindsey 21**. Vice President, Niskanen Center; Writes for Brookings, “Why Intellectual Property and Pandemics Don’t Mix,” Brookings, June 3, 2021, <https://www.brookings.edu/blog/up-front/2021/06/03/why-intellectual-property-and-pandemics-dont-mix/>, RJP, **DebateDrills**.

Although focusing on these immediate constraints is vital, we cannot confine our attention to the short term. First of all, the COVID-19 pandemic is far from over. Although Americans can now see the light at the end of the tunnel thanks to the rapid rollout of vaccines, most of the world isn’t so lucky. The virus is [currently raging in India and throughout South America](https://www.nytimes.com/interactive/2021/world/covid-cases.html), overwhelming health care systems and inflicting suffering and loss on a horrific scale. And consider the fact that Australia, which has been successful in suppressing the virus, recently announced it was sticking to plans to keep its borders closed until mid-2022. Criticisms of the TRIPS waiver that focus only on the next few months are therefore short-sighted: this pandemic could well drag on long enough for elimination of patent restrictions to enable new vaccine producers to make a positive difference.

Furthermore, and probably even more important, this is almost certainly not the last pandemic we will face. Urbanization, the spread of factory-farming methods, and globalization all combine to increase the odds that a new virus will make the jump from animals to humans and then spread rapidly around the world. Prior to the current pandemic, the 21st century already saw outbreaks of SARS, H1N1, MERS, and Ebola. Everything we do and learn in the current crisis should be viewed from the perspective of getting ready for next time.

#### A temporary waiver is sufficient---it creates momentum for America to repeat against harsher future pandemics which spills over

Nancy S. **Jecker &** Caesar A. **Atuire 21**. \*Department of Bioethics & Humanities, University of Washington School of Medicine, \*\*Department of Philosophy, University of Johannesburg, Auckland Park, Gauteng, South Africa, “What’s yours is ours: waiving intellectual property protections for COVID-19 vaccines,” Journal of Medical Ethics, July 6, 2021, <https://jme.bmj.com/content/medethics/early/2021/07/06/medethics-2021-107555.full.pdf>., RJP, **DebateDrills.**

The extraordinary circumstances of a global pandemic demand more than minimal or even moderate social responsibility. Everyone in a position to help must show the high degree of social responsibility the moment calls for. Governments, especially in wealthy nations, should stand up to influence peddling by pharmaceutical companies,26 and should do their part, beginning with WTO members voting for a temporary waiver to IP protections for COVID-19 vaccines.

Against our proposal it might be claimed a temporary waiver is not enough. Manufacturing COVID-19 vaccines requires technical know-how, technology, raw materials and equipment, which are lacking in many LMICs. Pfizer, for example, says its vaccine requires 280 components from 86 suppliers in 19 countries, along with specialised equipment and trained personnel.27 Since it takes more than simply waiving IP to vaccinate the world, what good is a temporary waiver?

In response, we agree temporarily losing the right to exclude companies from manufacturing vaccines is not enough. However, it can help break the logjam, creating a climate favourable to investment, since it removes the threat of being sued or prosecuted. Expedient investment strategies should focus on developing and repurposing existing capacities; Guzman notes that some middle-income countries are already producing COVID-19 vaccines, and some manufacturers in LMICs are already able to manufacture viral vector vaccines, such as AstraZeneca’s, and to contribute to the fill-and-finish stage of vaccine production.28

#### Future pandemics at 10x more deadly – absent a solution we’re all going to die

Ceballos 5/27 Gerardo Ceballos [PhD, Dr Gerardo Ceballos is an ecologist and conservationist at the Universidad Nacional Autonoma de Mexico. He is particularly recognized for his influential work on global patterns of distribution of diversity, endemism, and extinction risk in vertebrates. He is also well-known for his contribution to understanding the magnitude and impacts of the sixth mass extinction.], 5/27/21, “THE SIXTH MASS EXTINCTION AND THE FUTURE OF HUMANITY”, Population Matters, <https://populationmatters.org/news/2021/05/sixth-mass-extinction-and-future-humanity> DD AG

Somewhere, sometime in late 2019, a coronavirus from a wild species, perhaps a bat or a pangolin, infected a human in China. This could have been an obscure event, lost without trace in the annals of history, as it is very likely this has occurred many times in the last centuries. But this particular event was somehow different. The coronavirus became an epidemic first and a pandemic later. Covid-19 became the worst pandemic since the Spanish flu in 1918. The horrific human suffering it has caused, and its economic, social and political impacts, are still unraveling.

The reason Covid-19 and more than forty other very dangerous viruses, such as Lassa fever, HIV and Ebola, have jumped from wild animals to humans in the last four decades is the destruction of natural environments and the trafficking and consumption of wild animals.

The wildlife trade is to satisfy the insatiable and extravagant demand for these species in the Asian market, in countries such as China, Vietnam and Indonesia. The illegal wildlife trade is a gigantic business. It is as lucrative as the drug trade, but without the legal implications. The immense appetite of China and other Asian societies for exotic animals has promoted exponential growth in trade and profits. Wild and domestic animals sold in “wet markets” are kept in unsanitary and unethical conditions. There, feces, urine and food waste from cages at the top spill into cages at the bottom, creating the perfect conditions for viruses to leap from wild animals to domestic animals and humans. Thousands of wildlife species or their products are traded annually.

Wildlife trade is one of several human impacts, including habitat loss and fragmentation, pollution, toxification and invasive species, that have caused the extinction of thousands of species and threaten many more. Indeed, most people are unaware that the current extinction crisis is unprecedented in human history. Extinction occurs when the last individual of a species dies. The UN recently estimated that one million species, such as the panda, the orangutan and the Sumatran rhino, are at risk of extinction.

The second finding is that population extinctions, which are the prelude to species extinctions, are occurring at very fast rates (Ceballos et al., 2017). Around 32 percent of a sample of 27,000 species have declining populations and have experienced massive geographic range contractions. Population extinctions are a very severe and widespread environmental problem which we have called “Biological Annihilation”.

Finally, our third finding indicates that the magnitude of the extinction crisis is underestimated because there are thousands of species on the brink of extinction (Ceballos et al., 2020). Those species will likely become extinct in the near future unless a massive conservation effort is launched soon.

Many times, people have asked me why we should care about the loss of a species. There are ethical, moral, philosophical, religious and other reasons to be concerned. But perhaps the one that is most tangible for most people is the loss of ecosystem services, which are the benefits that humans derive from the proper function of nature. Ecosystem services include the proper mix of gases in the atmosphere that support life on Earth, the quantity and quality of water, pollination of wild crops and plants, fertilization of the soil, and protection against emerging pests and diseases, among many others. Every time a species is lost, ecosystem services are likely to erode and human well-being is reduced.

The loss of so many ec osystems and species is pushing us towards the point of collapse of civilization. The good news is that there is still time to reduce the current extinction crisis. The species and ecosystems that we manage to save in the next 10 – 15 years will define the future of biodiversity and civilization. What it is at stake is the future of mankind.

#### Put your critiques away – the plan solves global vaccine shortages that are killing BIPOC the most

Public Citizen 21 – Public Citizen is a nonprofit consumer advocacy organization that champions the public interest in the halls of power. We defend democracy, resist corporate power and work to ensure that government works for the people – not for big corporations. Founded in 1971, we now have 500,000 members and supporters throughout the country; “Waiver of WTO Protections for Big Pharma Will Help U.S. Economic Recovery and Boost U.S. Employment”; APRIL 12, 2021; <https://www.citizen.org/article/waiver-of-wto-protections-for-big-pharma-will-help-u-s-economic-recovery-and-boost-u-s-employment/> //advay

The Biden administration is rightly focused on helping communities here most at risk of infection and death – particularly Black, Brown and Indigenous communities – but is viewed worldwide as leading the opposition to a waiver that African, Asian and Latin American countries mainly populated by people of color have determined is essential to protect their people. Especially after the United States was the main obstacle in the late 1990s to an HIV/AIDS WTO TRIPS waiver, the U.S role as leader of the COVID-19 waiver opposition is toxic. Millions of people in Africa and across the developing world were ravaged and died needlessly of AIDS, and economies lost decades of progress because U.S. opposition delayed the eventual clarification of TRIPS “flexibilities” in 2001 that made it possible for people in poor nations to get the medications that had made HIV a chronic, treatable disease in rich nations.

U.S. vaccine makers Pfizer and Moderna have refused partnerships with many qualified developing country producers, while China and Russia are widely sharing their vaccines and have become the go-to for developing countries. Pharma’s claims that developing nation firms don’t have technical knowledge or skills to produce vaccines based on these new technologies is wrong and racist. Global South firms obviously can make COVID-19 vaccines, because they ARE right now. But only under contract if originators allow it and with originators retaining control over how much is made and where it can be sold and at what price. For instance, J&J decided that 91% of vaccines that South African firm Aspen contract manufactures must be sold in the EU. Only 9% can be sold in South Africa. The only way to control COVID-19 is to build global production capacity: That is why more than 100 WTO member nations now support a waiver. The Trump administration led the EU, UK, Australia, Switzerland, and a handful of other nations to block negotiations on the proposal. The anti-waiver nations are among the few with enough advanced vaccine purchases to fully cover their populations and even more. The nations seeking the waiver are among the many worldwide that have no or limited vaccine supplies and that, under current production trends, are not expected to be able to vaccinate their populations until 2022-2024, if ever. Meanwhile, Chinese Sinovac and Sinopharm vaccines and Russia’s Sputnik-5 vaccine are becoming the go-to options for countries around the developing world. The Chinese and Russian companies, probably compelled by their governments, have engaged in significant tech and know-how transfer and partnerships with firms all over the world. But this is not an optimal solution, even just from a global health perspective. Recently, a top Chinese official admitted that vaccines developed in China have low levels of effectiveness against the disease, which means that the millions of people being inoculated with them could still contract the virus with the associated risks of generating variants that could make their way to the United States.

Around the world, there is growing fury about grotesque vaccine inequities between and within countries target with geopolitical implications as China and Russia engage in “vaccine diplomacy” and widely share technology while U.S. firms refuse and the U.S. government blocks 100 nations’ efforts to help themselves. This scenario fuels an anti-democratic, anti-West narrative from authoritarian governments framed on greed, nationalism and human rights abuses of a U.S. government putting pharma corporations ahead of the lives and livelihoods of billions of people. No matter that this is next-level cynical coming from China and Russia, it has powerful appeal in nations where Chinese and Russian vaccines are the only hope to be safe from COVID-19 and for economies to recover while the U.S. government is seen as actively blocking access to the COVID-19 vaccines and treatments that can now protect Americans.

### 1AC – Contention 2: Primacy

#### US vaccines are exceedingly more effective than alternatives, but lack of access causes other nations to pursue Chinese and Russian vaccines

Brown, 21, 7/5/2021, “U.S. Covid-19 'vaccine diplomacy' is catching up to China and Russia's efforts”, MSNBC, Hayes Brown is a writer and editor for MSNBC Daily, where he helps frame the news of the day for readers. He was previously at BuzzFeed News and holds a degree in international relations from Michigan State University, URL: <https://www.msnbc.com/opinion/u-s-covid-19-vaccine-diplomacy-catching-china-russia-s-n1272957>, KR

That’s a big difference compared to the United States, where the three vaccines in use have caused new cases of Covid-19 to plummet in the months since they’ve been rolled out. While no vaccine can fully prevent infection, the ones being administered in the U.S. are extremely effective — the two-shot Pfizer-BioNTech and Moderna mRNA-based vaccines each boast an efficacy rate of over 90 percent; the one-dose Johnson and Johnson-produced version is around 66.3 percent effective at preventing Covid-19 infections.

The main Chinese vaccines — Sinopharm and Sinovac — have relatively lower efficacy rates, at 78 and 51 percent respectively. But that isn’t to say that the Chinese-made vaccines are worthless or garbage — compared to the alternative, they’re clearly much needed and appreciated as they still manage to keep many infections from developing into severe, life-threatening cases.

It’s less clear now whether the deals in place were all that good for Moscow and Beijing’s clients.

That’s definitely more than can be said for Sputnik V, the Russian-made coronavirus vaccine. Like China, Russia has doled out doses of its vaccine to friendly countries around the globe like Hungary, the Philippines and Bolivia. The World Health Organization has yet to sign off on the drug, though, despite it being billed as the “world’s first registered Covid-19 vaccine.”

And at home, Russians seem extremely skeptical of Sputnik and the two other Russian Covid-19 vaccines. NBC News reported last week that “Russia's vaccination rate is one of the lowest in countries where vaccines are widely available”:

Just 14 percent of Russia’s 146 million people have been vaccinated with at least one dose, compared to 53.5 percent of Americans, according to Our World in Data, a monitoring project based at the University of Oxford.

An ambitious plan to vaccinate 30 million Russians by June — which involved giving away cars and free groceries — has fallen short by a third.

South Africa’s government has shown interest in purchasing doses of Sputnik V from Moscow, despite its reported reduced effectiveness against the beta variant of Covid-19 that first appeared there. The developer of Sputnik says that the vaccine shows less of a drop in efficacy against the beta variant than other vaccines and is thus “much more preferable.” The South African Health Products Regulatory Authority has also yet to clear Sputnik V or Sinovac for use in the country.

#### Vaccine diplomacy is key to US spheres of influence – the aff creates incentives for other countries to align with US primacy

**Smith 21**, “Russia and China are beating the U.S. at vaccine diplomacy, experts say”, NBC News, 4/2, Alexander Smith: He is a senior reporter at NBC News Digital, where he has worked since 2013. He won an Emmy in 2015 as part of the team that covered the downing of Malaysia Airlines flight MH17. In 2017 he won the Society of Professional Journalists' Sigma Delta Chi Award as part of the NBC News Digital team covering the Brussels terror attacks, URL: <https://www.nbcnews.com/news/world/russia-china-are-beating-u-s-vaccine-diplomacy-experts-say-n1262742>, KR

Soon after Moscow sold 5.2 million doses of its Sputnik V vaccine, President Vladimir Putin was on the phone with his Bolivian counterpart, Luis Arce, in late January, discussing topics as varied as building a nuclear power plant to lithium mining and gas reserves.

In North Africa, Algeria didn't pay a dime for the Chinese vaccines that arrived in March. What it did offer was to support Beijing's "core interests" and oppose interference in its "internal affairs" — language China has used to defend against criticism over Hong Kong's autonomy and allegations of human rights abuses in Xinjiang, which it denies.

Although China and Russia deny it, experts say they are beginning to see how Beijing's and Moscow's strategy of selling or donating their vaccines abroad is greasing the wheels of their international relationships and allowing them to expand their influence throughout the world.

It's a development that should cause grave concern for the United States and other democracies, according to former U.S. ambassadors and other ex-diplomats.

What rankles these observers is not that China and Russia are winning at vaccine diplomacy, it's that the U.S. and others aren't even in the game yet. Washington and its allies have instead chosen to prioritize their domestic populations, keeping most doses at home and causing resentment abroad.

"The United States, until recently, was the go-to country for any major health disaster," said Thomas Shannon, the former U.S. undersecretary of state for political affairs, the third-highest-ranking role in the State Department. "So to pull itself off the playing field is very disconcerting."

Shannon, who served in the administrations of presidents George W. Bush, Barack Obama and Donald Trump and was ambassador to Brazil from 2010 to 2013, said Trump's decision to step back from the international Covid-19 response has sent a "chilling and worrisome message to many countries that find themselves at a very vulnerable moment."

Unless that changes under President Joe Biden and into the future, "the world will realize we're not a reliable partner, and that would be dangerous for us," he said. "I believe it's something that will be remembered."

'Extremely narrow-minded'

Few would argue that sending lifesaving vaccines around the world is a bad thing.

"We're not talking arms sales here," said John Campbell, who was the U.S. ambassador to Nigeria from 2004 to 2007. "We're talking about something citizens around the world want and desperately need."

Indeed both countries deny exporting vaccines for diplomatic gain.

This idea is "extremely narrow-minded," Guo Weimin, spokesman for the Chinese People's Political Consultative Conference, said at its annual meeting last month. President Xi Jinping has vowed to make vaccines a "global public good."

Similarly, Kremlin spokesman Dmitry Peskov has said that Russia merely believes "there should be as many doses of vaccines as possible" so "all countries, including the poorest, have the opportunity to stop the pandemic."

After a cloud of skepticism, recent studies suggest that the state-made vaccines, China's Sinopharm and Russia's Sputnik V program, are as effective as others. They have been approved by dozens of regulators.

Of the near 250 million vaccine doses it had produced so far, China has sent 118 million to 49 countries, according to Airfinity, a pharmaceuticals analytics company based in London.

Russia has sent vaccines to 22 different countries, and India has exported or donated 64 million of the nearly 150 million shots it has produced, according to Airfinity, which some experts interpret as New Delhi's attempt to counterbalance the vaccine diplomacy overtures of its regional rival, Beijing.

By contrast, the U.S. has delivered just over 200 million vaccine doses to is own population, according to the Centers for Disease Control and Prevention. It has agreed to share only a tiny number — around 4 million AstraZeneca-Oxford University shots that it wasn't using anyway — with Mexico and Canada.

The West's own vaccine nationalism has created a vacuum in which lower-and middle-income countries have been unable to get access to shots. And Beijing and Moscow have been only too happy to step in.

'Political suicide'

The majority of Chinese and Russian vaccine doses have gone "where Western powers and Russia and China have been competing for years for more influence," said Agathe Demarais the global forecasting director at the Economist Intelligence Unit, a research group based in London.

One key battleground is Egypt, which gets $1.3 billion in U.S. aid every year but whose human rights situation has led to strained ties with the West. It ordered tens of millions of doses from Pfizer, AstraZeneca, Sinopharm and Russia's Sputnik V program. But the first to arrive in Cairo in January were from China.

"For the man on the street" in African countries using the vaccines, "Russia and China become somewhat more attractive as possible models for going forward," said Campbell, the former ambassador to Nigeria. "Arguably, it will help increase the attractiveness of authoritarian forms of government at the expense of more democratic forms of government."

The pandemic has also allowed Russia to build relationships in Latin America beyond its traditional foothold of Venezuela, Shannon said, while the call between the Russian and Bolivian presidents was clearly linked to their vaccine deal, Demarais said. The Bolivian presidency didn't respond to a request for comment.

#### Absent the plan we risk great power war with China – transition to multipolarity in specific regions collapses deterrence and causes war – even if multipolarity in general is good, specific competition over competing regions ignites conflict

**Forsyth 19** [Jim Forsyth currently serves as dean of Air Command and Staff College, Maxwell AFB, Alabama. He earned his PhD from the University of Denver, Josef Korbel School of International Studies. He has written and published extensively on great power war, intervention, and nuclear issues. “Through the Glass—Darker”, Strategic Studies Quarterly , Vol. 13, No. 4 (WINTER 2019), pp. 18-36, JSTOR]//recut SLC PK

As the article argued in 2007, “technological shifts have continuously altered the methods of war,” but in the end, “political arrangements matter, and the deterrent effect of any weapon should be evaluated within the context of the structure of the international system.”20 This claim is as true now as it was then. Indeed, one might conclude that structure matters even more now than it did 10 years ago, given the shift to multipolarity.21 Under “lopsided” multipolarity—where the United States outweighs both China and Russia militarily—it will maintain power advantages on some fronts, but at smaller margins than it did during the unipolar moment when it reigned supreme. Power diffusion, and related great power competition concerns, will be governed by the continued growth of Asian economic and military clout predominantly from China and India and the relative decline of Western economic influence.22 As China continues to translate economic gains into military modernization, the US will “focus mainly on countering China.”23 Avoiding the perils of security competition will require that the US be more cautious about exercising its power abroad.24

Yet exercising diplomacy and restraint could prove to be challenging. Even scholars who adopt a more circumspect view of emerging multipolarity, and the implications of growing military-technological parity, acknowledge its underlying risks. Barry Posen, who questions the assumption that multipolarity is inherently unstable, nonetheless acknowledges that growing parity will only “mute” great power competition. The diffusion of power will not eradicate “great power adventures.”25 China’s rise is apt to entail alliance reconfigurations and temptations to employ conventional military power.26 In fact, just as the original article predicted, the United States and India, Russia and China, and France and Germany have taken steps toward tightening their security relationships. China’s progress toward narrowing its power gap with the US has already met with a return to US defense budget growth and the establishment of new US defense cooperation commitments—notably with India. In parallel, China and Russia have grown closer, with Presidents Xi Jinping and Vladimir Putin meeting three times in 2018 and China sending a “strong supporting contingent” to Russia’s Vostok-2018 military exercises.27

Given the complexities and uncertainties of multipolarity, the US arsenal of advanced conventional weapons (and those of other great powers) may not only prove ill suited to deterring great power war but also provide occasion for its inadvertent onset. The stealth, speed, and lethality of advanced conventional technologies—allowing for quick and decisive US victories in the Persian Gulf (1991), Kosovo (1999), and Afghanistan (2001)—have proven increasingly enticing to other great powers. Russia and China drew similar lessons from these conflicts, each embarking on military modernization programs geared toward antiaccess/area-denial (A2/AD) and grey zone strategies.28 Advanced conventional weapons already undergird Russia’s and China’s respective salami-slicing campaigns in Eastern Europe and the South China Sea. Russia began modernizing its military following its 2008 war with Georgia, enhancing its ground force readiness and updating its integrated air defense system. The improvements have allowed for significant defensive and force-projection gains (against border states).29 Though Russia has since dialed back modernization efforts in the wake of its economic downturn, China continues to seek avenues for undermining the United States’ conventional weapons edge. The People’s Liberation Army (PLA) still trails the United States in the areas of innovation and operational proficiency. Its modernization achievements, though—especially the development of intermediate-range missiles that threaten US forward bases and carrier strike groups—have substantially augmented China’s “advantage of proximity in most plausible conflict scenarios.”30

As great power rivals continue to chip away at the United States’ once considerable smart-weapons advantage, national security experts are reevaluating the viability of deterrence. On this front, the diffusion of capabilities, as well as the expansion of competition to the space and cyber domains, do more than complicate appraisals of the balance of power; they threaten to upend the foundations of deterrence.31 The arrival of dualcapable hypersonic weapons (and delivery systems)—currently being designed and tested by the US, China, and Russia—will arguably risk jeopardizing strategic stability. Their ultrahigh velocity could reduce warning time to the extent that “a response would be required on first signal of attack”; likewise, their deployment in ready-to-launch mode could trigger preemptive strikes, as others might perceive it as a sign of impending attack.32 Further, cyber weapons’ potential for disabling an opponent’s “early warning and command systems” may diminish the expected costs of first strike under crisis conditions.33 Autonomous weapons also have the potential to fundamentally alter the psychological underpinnings of strategy And, as Kenneth Payne notes, there is no “a priori reason” to expect that substituting artificial intelligence (AI) for human intelligence—that rapid, accurate, and unbiased information processing and responses—“will necessarily be safer.” Because AI limits the risks of using force, it could make conflict more acceptable to risk-averse states; because its speed and precision favor the offense, it could prove more conducive to aggression than deterrence; and because it shapes a host of processes and technologies rather than a single weapon or system, its effects on strategy (and the challenges of its regulation) could prove counter to deterrence.34

As noted in the original article, nuclear weapons helped sustain the “cold peace” during the Cold War—not because of their awesome destructive power but because that awesome destructive power helped buttress bipolarity.35 The simplicity of bipolarity and superpower balancing, in turn, limited “the dangers of miscalculation and overreaction.”36 Multipolarity, though, makes for complexity; additional great power players provide additional opportunities for miscalculation and overreaction. Given these conditions and the perceived “usability” of advanced conventional weapons relative to nuclear weapons, it seems likely that they will fall short of yielding “the kinds of political structures necessary to enhance deterrence.”37 To counter Posen, the diffusion of advanced conventional technology may well have cheapened the near-term costs and risks of going to war, and particularly engaging in hybrid warfare. Even if the US manages to avoid a direct confrontation with Russia or China, it seems increasingly plausible that it could be dragged into a conflict involving one or more of their allies.

#### US-China war goes nuclear.

[Caitlin Talmadge (10-15-2018), PhD in Political Science from MIT, BA in Government from Harvard, Professor of Security Studies at Georgetown University, “Beijing’s Nuclear Option,” Foreign Affairs, [https://www.foreignaffairs.com/articles/china/2018-10-15/beijings-nuclear-option]//recut](https://www.foreignaffairs.com/articles/china/2018-10-15/beijings-nuclear-option%5d//recut) SLC PK

As China’s power has grown in recent years, so, too, has the risk of war with the United States. Under President Xi Jinping, China has increased its political and economic pressure on Taiwan and built military installations on coral reefs in the South China Sea, fueling Washington’s fears that Chinese expansionism will threaten U.S. allies and influence in the region. U.S. destroyers have transited the Taiwan Strait, to loud protests from Beijing. American policymakers have wondered aloud whether they should send an aircraft carrier through the strait as well. Chinese fighter jets have intercepted U.S. aircraft in the skies above the South China Sea. Meanwhile, U.S. President Donald Trump has brought long-simmering economic disputes to a rolling boil.

A war between the two countries remains unlikely, but the prospect of a military confrontation—resulting, for example, from a Chinese campaign against Taiwan—no longer seems as implausible as it once did. And the odds of such a confrontation going nuclear are higher than most policymakers and analysts think.

Members of China’s strategic com­munity tend to dismiss such concerns. Likewise, U.S. studies of a potential war with China often exclude nuclear weapons from the analysis entirely, treating them as basically irrelevant to the course of a conflict. Asked about the issue in 2015, Dennis Blair, the former commander of U.S. forces in the Indo-Pacific, estimated the likelihood of a U.S.-Chinese nuclear crisis as “somewhere between nil and zero.”

This assurance is misguided. If deployed against China, the Pentagon’s preferred style of conventional warfare would be a potential recipe for nuclear escalation. Since the end of the Cold War, the United States’ signature approach to war has been simple: punch deep into enemy territory in order to rapidly knock out the opponent’s key military assets at minimal cost. But the Pentagon developed this formula in wars against Afghanistan, Iraq, Libya, and Serbia, none of which was a nuclear power.

China, by contrast, not only has nuclear weapons; it has also intermingled them with its conventional military forces, making it difficult to attack one without attacking the other. This means that a major U.S. military campaign targeting China’s conventional forces would likely also threaten its nuclear arsenal. Faced with such a threat, Chinese leaders could decide to use their nuclear weapons while they were still able to.

As U.S. and Chinese leaders navigate a relationship fraught with mutual suspicion, they must come to grips with the fact that a conventional war could skid into a nuclear confrontation. Although this risk is not high in absolute terms, its consequences for the region and the world would be devastating. As long as the United States and China continue to pursue their current grand strategies, the risk is likely to endure. This means that leaders on both sides should dispense with the illusion that they can easily fight a limited war. They should focus instead on managing or resolving the political, economic, and military tensions that might lead to a conflict in the first place.

#### Extinction – nuclear winter, crude oil amplifies, smoke covers the world

Snydera and Ruyle 17 (Brian F.Snydera and Leslie E. Ruyle, 12-15-2017, [Brian F. Snyder. Department of Environmental Science, Louisiana State University, United States. Leslie E. Ruyle. Center on Conflict and Development, Texas A&M University, United States]"The abolition of war as a goal of environmental policy," No Publication, [https://www.sciencedirect.com/science/article/pii/S0048969717316431?via%3Dihub)//SLC](https://www.sciencedirect.com/science/article/pii/S0048969717316431?via%3Dihub)//CHS) PK

While the precise impacts of a hypothetical nuclear war are difficult to predict, the detonation of the world's nuclear weapons would plausibly kill all or nearly all humans on Earth and initiate a mass extinction event. There are a total of about 9400 nuclear warheads in active service around the world, with approximately 8300 of these weapons in U.S. and Russian arsenals (Kristensen and Norris, 2017a). Because of government secrecy, it is difficult to reliably estimate the total explosive power contained in these warheads, but in most cases, each warhead ranges between 100 and 1200 kt of TNT equivalent (for comparison, the bombs dropped on Hiroshima and Nagasaki had yields of approximately 15–20 kt). The combined arsenals of the U.S. and Russia likely have a yield of at least 2–3 billion tons of TNT equivalent (Kristensen and Norris, 2017b,c). 2.1. Nuclear winter In the 1980s climate scientists used simple and early climate models to estimate the effects of large-scale nuclear wars on climate. The estimates they derived were catastrophic. For example, Turco et al. (1983) reported temperature reductions of 43 °C for 4 months in the Northern Hemisphere following nuclear war using the explosive power of 10 billion tons of TNT.1 As the cold war ended, interest in modelling the climate effects of nuclear war declined and some policy-makers considered the threat of nuclear winter to be either disproved or exaggerated (Martin, 1988). Toon et al. (2007) and Robock et al. (2007) reignited interest in the climate effects of nuclear war. Toon et al. (2008) modeled the effects of a medium scale nuclear war with a total explosive yield of 440 million tons of explosive yield (far less than current U.S. and Russian arsenals) and estimated global soot2 emissions of 180 Tg. Using a more conservative estimate of 150 Tg of soot, Toon et al. estimated that this emission would be sufficient to reduce global temperatures by about 8 °C and energy flux by 150 W/m2 ; for comparison, the cumulative greenhouse gas emissions to the atmosphere since the industrial revolution have increased energy flux by 3 W/m2 (Butler and Montzka, 2017). Robock et al. (2007) modeled a similar 150 Tg smoke emission and found similar results including temperature reduction of about 8 °C lasting for several years. Low temperatures reduced evapotranspiration and weakened the global hydrological cycle and Hadley cells. As a result, precipitation decreased globally by 45% with especially dramatic decreases in the agricultural areas of the United States. In the Northern Hemisphere, growing seasons would be shortened by about 100 days for about 3 years. This would preclude most food production over most of the world for several years. Mills et al. (2014) conducted a detailed analysis of the effects of a small (1.5 million ton) regional exchange lofting just 5 Tg of soot into the atmosphere. This war would be equivalent to an exchange of 100 Hiroshima-sized bombs between, for example, India, Pakistan, or China. Mills et al. found global temperature decreases of 1.6 °C. To our knowledge, no one has studied the effects of a multi-billion ton nuclear exchange using modern atmospheric models. If, as Toon et al. and Robock et al. suggest, a 440 million ton war results in temperature reductions of 8 °C for a decade and a 100 day reduction in the growing season, it is reasonable to assume that a one to five billion ton war would not be survivable for the majority of people on earth. However, as populations and population centers grow, the effects of nuclear wars on the biosphere will also grow. The consequences of nuclear winter increase as the amount of fuel (buildings, cars, biomass, liquid and solid fuels) added to a targeted area increase. As population centers grow and densify over time, the amount of soot added to the stratosphere as the result of any given nuclear exchange may increase (depending in part on building materials). As a result, the nuclear winter resulting from a 400 million ton yield global war in 2020 may be far more severe than if the same war occurred in 2000. Further, there are reasons to believe that the soot emissions from a hypothetical nuclear exchange are conservative because they focus on urban areas and often do not incorporate non-urban energy infrastructure. For example, if ignited and burned completely, the U.S. Strategic Petroleum Reserve (SPR) alone contains about 14.5 Tg of soot emissions.3 Including all crude held in U.S. commercial facilities, the potential soot emissions increase to 24 Tg. Thus, incorporating crude oil storage in the U.S. alone would increase soot generation estimates by about 16%. Similarly, nuclear war planners would be likely to target coal, oil and gas fields in the U.S., Russia, and their allies. This unaccounted for fuel could increase the total soot contribution to the atmosphere, potentially deepening the resulting nuclear winter. 2.2. Acute effects of particulate matter Studies of nuclear winter typically focus on the effects of smoke lofted into the stratosphere during nuclear firestorms. However, a larger proportion of smoke following nuclear war will be trapped in the troposphere where it would have significantly acute impacts on human and non-human species. Crutzen et al. (1984) calculated that following a major nuclear war (about 5 billion tons of explosives, roughly the combined U.S. and Russian deployed nuclear arms as of 2017) smoke would cover about 30–40% of the earth's surface with airborne smoke concentrations on the order of 5 mg/m3 . While initially this smoke would be composed of very small particles (b0.1 μm), the particles would rapidly coalesce into the 0.1 to 3 μm range, roughly consistent with the wellstudied PM2.5. For comparison, the EPA's National Ambient Air Quality standard for PM2.5 is 0.012 mg/m3 and as of 2017, the highest PM2.5 concentrations in Asia are typically around 0.3 to 1 mg/m3 .

### 1AC – Solvency:

#### Thus the plan: The United States of America ought to reduce intellectual property protections for the COVID-19 vaccine. The plan’s implemented through a COVID waiver for the U.S.

-- that’s Moderna, Pfizer-BioNTech, Johnson & Johnson/Janssen

#### The patent system for pandemic-related drugs is currently out of balance---there’s spurious over-patenting under the guise of innovation, which paradoxically hurts innovation by juicing profits. A temporary waiver in the U.S. for pandemics rebalance the system.

Brink **Lindsey 21**. Vice President, Niskanen Center; Writes for Brookings, “Why Intellectual Property and Pandemics Don’t Mix,” Brookings, June 3, 2021, <https://www.brookings.edu/blog/up-front/2021/06/03/why-intellectual-property-and-pandemics-dont-mix/>, RJP, **DebateDrills**.

When we take the longer view, we can see a fundamental mismatch between the policy design of intellectual property protection and the policy requirements of effective pandemic response. Although patent law, properly restrained, constitutes one important element of a well-designed national innovation system, the way it goes about encouraging technological progress is singularly ill-suited to the emergency conditions of a pandemic or other public health crisis. Securing a TRIPS waiver for COVID-19 vaccines and treatments would thus establish a salutary precedent that, in emergencies of this kind, governments should employ other, more direct means to incentivize the development of new drugs. Here is the basic bargain offered by patent law: encourage the creation of useful new ideas for the long run by slowing the diffusion of useful new ideas in the short run. The second half of the bargain, the half that imposes costs on society, comes from the temporary exclusive rights, or monopoly privileges, that a patent holder enjoys. Under U.S. patent law, for a period of 20 years nobody else can manufacture or sell the patented product without the permission of the patent holder. This allows the patent holder to block competitors from the market, or extract licensing fees before allowing them to enter, and consequently charge above-market prices to its customers. Patent rights thus slow the diffusion of a new invention by restricting output and raising prices.The imposition of these short-run costs, however, can bring net long-term benefits by sharpening the incentives to invent new products. In the absence of patent protection, the prospect of easy imitation by later market entrants can deter would-be innovators from incurring the up-front fixed costs of research and development. But with a guaranteed period of market exclusivity, inventors can proceed with greater confidence that they will be able to recoup their investment.For the tradeoff between costs and benefits to come out positive on net, patent law must strike the right balance. Exclusive rights should be valuable enough to encourage greater innovation, but not so easily granted or extensive in scope or term that this encouragement is outweighed by output restrictions on the patented product and discouragement of downstream innovations dependent on access to the patented technology.Unfortunately, the U.S. patent system at present is out of balance. Over the past few decades, the expansion of patentability to include software and business methods as well as a general relaxation of patenting requirements have led to wildly excessive growth in these temporary monopolies: the number of patents granted annually has [skyrocketed roughly fivefold](https://www.uspto.gov/web/offices/ac/ido/oeip/taf/us_stat.htm) since the early 1980s. One unfortunate result has been the rise of “non-practicing entities,” better known as patent trolls: firms that make nothing themselves but buy up patent portfolios and monetize them through aggressive litigation. As a result, a law that is supposed to encourage innovation has turned into a [legal minefield](https://scholarship.law.cornell.edu/cgi/viewcontent.cgi?article=4620&context=clr) for many would-be innovators. In the pharmaceutical industry, firms have abused the law by piling up patents for trivial, therapeutically irrelevant “innovations” that allow them to [extend their monopolies](https://www.i-mak.org/wp-content/uploads/2018/08/I-MAK-Overpatented-Overpriced-Report.pdf) and keep raising prices long beyond the statutorily contemplated 20 years. Patent law is creating these unintended consequences because policymakers have been caught in an ideological fog that [conflates “intellectual property” with actual property rights](https://www.niskanencenter.org/wp-content/uploads/2019/09/LT_IPMisnomer-2-1.pdf) over physical objects. Enveloped in that fog, they regard any attempts to put limits on patent monopolies as attacks on private property and view ongoing expansions of patent privileges as necessary to keep innovation from grinding to a halt. In fact, patent law is a tool of regulatory policy with the usual tradeoffs between costs and benefits; like all tools, it can be misused, and as with all tools there are some jobs for which other tools are better suited. A well-designed patent system, in which benefits are maximized and costs kept to a minimum, is just one of various policy options that governments can employ to stimulate technological advance—including tax credits for R&D, prizes for targeted inventions, and direct government support.

#### The plan seamlessly shifts to a direct support model during pandemics, which allows pharma companies to profit and innovate while speeding up the process---that solves but avoids the innovation DA.

Brink **Lindsey 21**. Vice President, Niskanen Center; Writes for Brookings, “Why Intellectual Property and Pandemics Don’t Mix,” Brookings, June 3, 2021, <https://www.brookings.edu/blog/up-front/2021/06/03/why-intellectual-property-and-pandemics-dont-mix/>, RJP, **DebateDrills**.

**PUBLIC HEALTH EMERGENCIES AND DIRECT GOVERNMENT SUPPORT**

For pandemics and other public health emergencies, patents’ mix of costs and benefits is misaligned with what is needed for an effective policy response. The basic patent bargain, even when well struck, is to pay for more innovation down the road with slower diffusion of innovation today. In the context of a pandemic, that bargain is a bad one and should be rejected entirely. Here the imperative is to accelerate the diffusion of vaccines and other treatments, not slow it down. Giving drug companies the power to hold things up by blocking competitors and raising prices pushes in the completely wrong direction.

What approach to encouraging innovation should we take instead? How do we incentivize drug makers to undertake the hefty R&D costs to develop new vaccines without giving them exclusive rights over their production and sale? The most effective approach during a public health crisis is direct government support: public funding of R&D, advance purchase commitments by the government to buy large numbers of doses at set prices, and other, related payouts. And when we pay drug makers, we should not hesitate to pay generously, even extravagantly: we want to offer drug companies big profits so that they prioritize this work above everything else, and so that they are ready and eager to come to the rescue again the next time there’s a crisis.

It was direct support via Operation Warp Speed that made possible the astonishingly rapid development of COVID-19 vaccines and then facilitated a relatively rapid rollout of vaccine distribution (relative, that is, to most of the rest of the world). And it’s worth noting that a major reason for the faster rollout here and in the United Kingdom compared to the European Union was the latter’s [misguided penny-pinching](https://www.nytimes.com/2021/05/17/opinion/europe-vaccines-commission.html?smid=tw-share). The EU bargained hard with firms to keep vaccine prices low, and as a result their citizens ended up in the back of the queue as various supply line kinks were being ironed out. This is particularly ironic since the Pfizer-BioNTech vaccine was developed in Germany. As this fact underscores, the chief advantage of direct support isn’t to “get tough” with drug firms and keep a lid on their profits. Instead, it is to accelerate the end of the public health emergency by making sure drug makers profit handsomely from doing the right thing.

Patent law and direct support should be seen not as either-or alternatives but as complements that apply different incentives to different circumstances and time horizons. Patent law provides a decentralized system for encouraging innovation. The government doesn’t presume to tell the industry which new drugs are needed; it simply incentivizes the development of whatever new drugs that pharmaceutical firms can come up with by offering them a temporary monopoly. It is important to note that patent law’s incentives offer no commercial guarantees. Yes, you can block other competitors for a number of years, but that still doesn’t ensure enough consumer demand for the new product to make it profitable. DIRECT SUPPORT MAKES PATENTS REDUNDANT The situation is different in a pandemic. Here the government knows exactly what it wants to incentivize: the creation of vaccines to prevent the spread of a specific virus and other drugs to treat that virus. Under these circumstances, the decentralized approach isn’t good enough. There is no time to sit back and let drug makers take the initiative on their own timeline. Instead, the government needs to be more involved to incentivize specific innovations now. As recompense for letting it call the shots (pardon the pun), the government sweetens the deal for drug companies by insulating them from commercial risk. If pharmaceutical firms develop effective vaccines and therapies, the government will buy large, predetermined quantities at prices set high enough to guarantee a healthy return.

#### ONLY the plan solves current and future vaccine access.

#### 1] The plan bolsters the number of vaccines---arguments about supply and logistics are empirically disproven.

Nancy S. **Jecker &** Caesar A. **Atuire 21**. \*Department of Bioethics & Humanities, University of Washington School of Medicine, \*\*Department of Philosophy, University of Johannesburg, Auckland Park, Gauteng, South Africa, “What’s yours is ours: waiving intellectual property protections for COVID-19 vaccines,” Journal of Medical Ethics, July 6, 2021, <https://jme.bmj.com/content/medethics/early/2021/07/06/medethics-2021-107555.full.pdf>., RJP, **DebateDrills.**

Since consequentialist justifications treat the value of IP as purely instrumental, they are also vulnerable to counterarguments showing that a sought-after goal is not the sole or most important end. During the COVID-19 pandemic, we submit that the vaccinating the world is an overriding goal. With existing IP protections intact, the world has fallen well short of this goal. Current forecasts show that at the current pace, there will not be enough vaccines to cover the world’s population until 2023 or 2024.15 IP protections further frustrate the goal of universal access to vaccines by limiting who can manufacturer them. The WHO reports that 80% of global sales for COVID-19 vaccines come from five large multinational corporations.16 Increasing the number of manufacturers globally would not only increase supply, but reduce prices, making vaccines more affordable to LMICs. It would stabilise supply, minimising disruptions of the kind that occurred when India halted vaccine exports amidst a surge of COVID-19 cases.

It might be objected that waiving IP protections will not increase supply, because it takes years to establish manufacturing capacity. However, since the pandemic began, we have learnt it takes less time. Repurposing facilities and vetting them for safety and quality can often happen in 6 or 7months, about half the time previously thought.17 Since COVID-19 will not be the last pandemic humanity faces, expanding manufacturing capacity is also necessary preparation for future pandemics. Nkengasong, Director of the African Centres for Disease Control and Prevention, put the point bluntly, ‘Can a continent of 1.2billion people—projected to be 2.4billion in 30 years, where one in four people in the world will be African—continue to import 99% of its vaccine?’18

#### 2] Compulsory licensing and status quo mechanisms are inefficient

Nancy S. **Jecker &** Caesar A. **Atuire 21**. \*Department of Bioethics & Humanities, University of Washington School of Medicine, \*\*Department of Philosophy, University of Johannesburg, Auckland Park, Gauteng, South Africa, “What’s yours is ours: waiving intellectual property protections for COVID-19 vaccines,” Journal of Medical Ethics, July 6, 2021, <https://jme.bmj.com/content/medethics/early/2021/07/06/medethics-2021-107555.full.pdf>., RJP, **DebateDrills, re-cut KR**

A proponent of IP protections may insist TRIPS already includes built-in exceptions adequate to the task. Article 31 grants governments rights to issue licenses for using a patent during the patent term without a patent holder’s consent. This exception was used 144 times between 2001 and 2016 to create flexibilities for 89 countries.29 In 2017, it was extended to allow licensed countries to export products to countries that lack production capacity. Isn’t that enough?

In reply, Article 31 will not take us very far. While useful for some applications, it is cumbersome. For example, for pharmaceutical products, after applying for an exception, exporting countries must prove products go only to destination nations, are readily identifiable based on variations of colour or shape, and include only product necessary to meet requirements of an eligible country; importing nations must notify the TRIPS council of receipt. Fulfilling these requirements would needlessly delay the vital task of vaccinating the world.

Finally, critics might point to the case of Moderna, which voluntarily pledged (in October 2020) not to enforce its patents during the pandemic. Since companies have not lined up to produce Moderna’s vaccine, doesn’t that show the ineptitude of temporary waivers? In reply, a single pledge by a single company is a start, but insufficient to catalyse the global changes needed. In conclusion, loosening the grip of IP protections is not a miracle fix, and there are many other barriers to a safer world. This paper filled a gap in current debates about IP protections for COVID-19 vaccines by focusing on ethics. In the final analysis, a temporary waiver of IP protections is the world’s best bet.

#### 3] Manufacturing – only waiver gives them legal access

**HRW 21,** 6/3/21, Humans Right Watch, “Seven Reasons the EU is Wrong to Oppose the TRIPS Waiver”, URL: <https://www.hrw.org/news/2021/06/03/seven-reasons-eu-wrong-oppose-trips-waiver>, KR

The European Commission claims that intellectual property (IP) is not a barrier to scaling up the manufacturing of vaccines or other health products needed for the Covid-19 response, suggesting that sharing IP would not immediately speed up manufacturing. Right now, there are manufacturers with capacity to produce additional Covid-19 vaccines and other health products at factories in Bangladesh, Canada, Denmark, India, and Israel, but they are unable to contribute because they do not yet have the right licenses. So, IP is a barrier to them. The TRIPS waiver proposal sponsors and experts at the leading science journal Nature, Médecins Sans Frontières (MSF) Access Campaign, the Third World Network, and others have presented many other concrete examples of how enforcement of IP rules blocked, delayed, or limited production of chemical reagents for Covid-19 tests, ventilator valves, Covid-19 treatments, and elements of Covid-19 vaccines. IP constraints have not only led to vaccine shortages but have also led to shortages of key raw materials like bioreactor bags and filters.

Rather than manufacturers being held back by an inherent lack of manufacturing and technological capability, studies have shown that transnational claims to IP impede new manufacturers from entering and competing in the market. The same dynamics are playing out today with Covid-19.

### FW

#### The standard is maximizing expected wellbeing.

#### Prefer:

#### 1] Actor specificity:

#### A] Aggregation – every policy benefits some and harms others, which also means side constraints freeze action.

#### B] No act-omission distinction – choosing to omit is an act itself – governments decide not to act which means being presented with the aff creates a choice between two actions, neither of which is an omission

#### 2] Lexical pre-requisite: threats to bodily security preclude the ability for moral actors to effectively act upon other moral theories since they are in a constant state of crisis that inhibits the ideal moral conditions which other theories presuppose

#### 3] Only consequentialism explains degrees of wrongness— there’s a difference in breaking a promise to meet up for lunch vs taking a dying person to the hospital but the moral obligations are the same w/o consequences

#### 4] Intuitions outweigh—they’re the foundational basis for any argument and theories that contradict our intuitions are most likely false even if we can’t deductively determine why.

#### 5] Phenomenal introspection --- it’s the most epistemically reliable --- historical moral disagreement over internal conceptions of morality such as questions of race, gender, class, religion, etc prove the fallibility of non-observational based ethics --- introspection means we value happiness because we can determine that we each value itt

### UV